96 research outputs found
Allergies professionnelles des boulangers. Etude de la sensibilisation aux farines dans un groupe d'apprentis boulangers et boulangers.
Les allergies sont très fréquentes au sein de la population générale puisque 30% ont un terrain atopique et 20% souffrent d'allergies (1).
Parmi ces allergies, il en existe qui concernent essentiellement les boulangers et autres corps de métier gravitant autour de la formation du pain et d'autres produits. Il s'agit de l'allergie aux farines et enzymes utilisées dans la fabrication de pain et d'autres produits contenant de la farine (2). Cette allergie peut atteindre les voies respiratoires avec l'asthme et la rhinite, les muqueuses oculaires (conjonctivite) et la peau (eczéma) (3,4). Ce sont essentiellement les farines de blé et de seigle qui sont responsables de l'asthme professionnel chez le boulanger (5,6). En ce qui concerne les enzymes, c'est principalement l'alpha-amylase qui cause l'asthme du boulanger (2).
L'allergie à la farine ou aux enzymes chez le boulanger est l'allergie professionnelle la plus fréquente en Suisse. Elle contraint bien trop souvent les allergiques à se réorienter professionnellement, principalement lorsqu'il y a de l'asthme. Notons que par crainte de perdre leur emploi et d'être obligés de se reconvertir, beaucoup de boulangers ne déclarent pas leur maladie (7). En effet, en Suisse, le nombre de personnes atteintes par un asthme professionnel n'a fait qu'augmenter durant le XXème Siècle et atteint chaque année plus de 100 personnes travaillant en boulangerie ou en pâtisserie. Plus de 50 d'entre elles doivent renoncer à leur activité et se réorienter professionnellement (8). Ces maladies sont souvent sous-déclarées, en particulier les rhinites qui passent souvent inaperçues (1).
Les recherches ont montré que le risque de développer de telles allergies augmente avec la concentration de farines et additifs dans l'air ambiant (8,9).
Le risque diffère en fonction de la présence ou non d'un terrain atopique. En effet, pour un travailleur non atopique ou non sensibilisé, la probabilité de développer des symptômes modérés du système respiratoire supérieur et la progression vers des symptômes sévères atteignant le système respiratoire inférieur s'élève à 0.4%, ce risque est deux fois supérieur pour un travailleur atopique (10).
En outre, parmi les personnes présentant une allergie professionnelle en boulangerie, 36% ont des symptômes sévères sur une sensibilisation à la farine et 22% sur une sensibilisation à l'alpha- amylase. Il faut en moyenne une période d'environ 10 ans pour développer des symptômes respiratoires (3)
A new approach to 'on-demand' treatment of lifelong premature ejaculation by treatment with a combination of a 5-HT 1A receptor antagonist and SSRI in rats.
Lifelong premature ejaculation (PE) in men lacks an adequate on-demand pharmacological treatment. Although selective serotonin reuptake inhibitors (SSRIs) are used for PE they only work after chronic treatment, or if used on-demand, less adequately than chronic SSRI treatment. It has been shown that the addition of a behaviorally silent 5-HT 1A-receptor antagonist to an SSRI can generate acute inhibitory effects on male rat sexual behavior. Atlas987 is a selective 5-HT 1A-receptor antagonist with equal potency to displace agonist and antagonist binding to pre- and post-synaptic 5-HT 1A receptors in rat and human brain. To investigate whether Atlas987 together with the SSRI paroxetine, a combination called Enduro, induces acute inhibitory effects on male rat sexual behavior, we tested Enduro in Wistar rats in a dose-dependent manner. We first tested the 5-HT 1A receptor antagonist Atlas987 in 8-OH-DPAT induced serotonergic behavior in rats. Second, we tested Enduro in a dose-dependent manner in male sexual behavior. Third, we tested the effective time window of Enduro's action, and lastly, we measured the plasma levels of Atlas987 and paroxetine over an 8-h period. Results showed that Enduro acutely and dose-dependently reduced the number of ejaculations and increased the ejaculation latencies. The behavioral pattern induced reflected a specific effect on sexual behavior excluding non-specific effects like sedation or sensoric-motoric disturbances. The time-window of activity of Enduro showed that this sexual inhibitory activity was at least found in a 1-4 h' time window after administration. Plasma levels showed that in this time frame both Atlas987 and paroxetine are present. In conclusion, in rats, Enduro is successful in acutely inhibiting sexual behavior. These results may be therapeutically attractive as "on demand" treatment for life-long premature ejaculation in men. </p
Quantum pumping: Coherent Rings versus Open Conductors
We examine adiabatic quantum pumping generated by an oscillating scatterer
embedded in a one-dimensional ballistic ring and compare it with pumping caused
by the same scatterer connected to external reservoirs. The pumped current for
an open conductor, paradoxically, is non-zero even in the limit of vanishing
transmission. In contrast, for the ring geometry the pumped current vanishes in
the limit of vanishing transmission. We explain this paradoxical result and
demonstrate that the physics underlying adiabatic pumping is the same in open
and in closed systems.Comment: 4 pages, 2 figure
Charge Fluctuations in Quantum Point Contacts and Chaotic Cavities in the Presence of Transport
We analyze the frequency-dependent current fluctuations induced into a gate
near a quantum point contact or a quantum chaotic cavity. We use a current and
charge conserving, effective scattering approach in which interactions are
treated in random phase approximation. The current fluctuations measured at a
nearby gate, coupled capacitively to the conductor, are determined by the
screened charge fluctuations of the conductor. Both the equilibrium and the
non-equilibrium current noise at the gate can be expressed with the help of
resistances which are related to the charge dynamics on the conductor. We
evaluate these resistances for a point contact and determine their
distributions for an ensemble of chaotic cavities. For a quantum point contact
these resistances exhibit pronounced oscillations with the opening of new
channels. For a chaotic cavity coupled to one channel point contacts the charge
relaxation resistance shows a broad distribution between 1/4 and 1/2 of a
resistance quantum. The non-equilibrium resistance exhibits a broad
distribution between zero and 1/4 of a resistance quantum.Comment: 9 pages, two-column Revtex, 6 figures include
Human embryonic stem cells and derived contractile embryoid bodies are susceptible to Coxsakievirus B infection and respond to interferon Iβ treatment
We studied the susceptibility of human embryonic stem cells and derived contractile embryoid bodies from WAO9, HUES-5 and HUES-16 cell lines to Coxsackievirus B infection. After validating stem cell-like properties and cardiac phenotype, Coxsackievirus B receptors CAR and DAF, as well as type I interferon receptors were detected in all cell lines and differentiation stages studied. Real-time PCR analysis showed that CAR mRNA levels were 3.4-fold higher in undifferentiated cells, while DAF transcript levels were 2.78-fold more abundant in differentiated cultures (P5-106 plaque forming units (PFU)/ml, the highest titers were detected in undifferentiated cells. Cell viability detected by a colorimetric assay, showed inverse correlation with infectivity titers of cell culture supernatants. Treatment with 100 U of interferon Iβ significantly reduced viral replication and associated cell death during a 24-48 h observation period, as detected by reduced infectivity titers in the supernatants and increased cell viability by a colorimetric assay, respectively. We propose human embryonic stem cell and derived contractile embryoid bodies as a valid model to study cardiac Coxsackievirus B infection.Instituto de Biotecnologia y Biologia MolecularFacultad de Ciencias Exacta
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
BACKGROUND: PQR309 is an orally bioavailable, balanced pan-phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor. PATIENTS AND METHODS: This is an accelerated titration, 3 + 3 dose-escalation, open-label phase I trial of continuous once-daily (OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in patients with advanced solid tumours. Primary objectives were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). RESULTS: Twenty-eight patients were included in six dosing cohorts and treated at a daily PQR309 dose ranging from 10 to 150 mg. Common adverse events (AEs; ≥30% patients) included fatigue, hyperglycaemia, nausea, diarrhoea, constipation, rash, anorexia and vomiting. Grade (G) 3 or 4 drug-related AEs were seen in 13 (46%) and three (11%) patients, respectively. Dose-limiting toxicity (DLT) was observed in two patients at 100 mg OD (>14-d interruption in PQR309 due to G3 rash, G2 hyperbilirubinaemia, G4 suicide attempt; dose reduction due to G3 fatigue, G2 diarrhoea, G4 transaminitis) and one patient at 80 mg (G3 hyperglycaemia >7 d). PK shows fast absorption (Tmax 1-2 h) and dose proportionality for Cmax and area under the curve. A partial response in a patient with metastatic thymus cancer, 24% disease volume reduction in a patient with sinonasal cancer and stable disease for more than 16 weeks in a patient with clear cell Bartholin's gland cancer were observed. CONCLUSION: The MTD and RP2D of PQR309 is 80 mg of orally OD. PK is dose-proportional. PD shows PI3K pathway phosphoprotein downregulation in paired tumour biopsies. Clinical activity was observed in patients with and without PI3K pathway dysregulation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov # NCT01940133
Scattering Theory of Photon-Assisted Electron Transport
The scattering matrix approach to phase-coherent transport is generalized to
nonlinear ac-transport. In photon-assisted electron transport it is often only
the dc-component of the current that is of experimental interest. But
ac-currents at all frequencies exist independently of whether they are measured
or not. We present a theory of photon-assisted electron transport which is
charge and current conserving for all Fourier components of the current. We
find that the photo-current can be considered as an up- and down-conversion of
the harmonic potentials associated with the displacement currents. As an
example explicit calculations are presented for a resonant double barrier
coupled to two reservoirs and capacitively coupled to a gate. Two experimental
situations are considered: in the first case the ac-field is applied via a
gate, and in the second case one of the contact potentials is modulated. For
the first case we show that the relative weight of the conduction sidebands
varies with the screening properties of the system. In contrast to the
non-interacting case the relative weights are not determined by Bessel
functions. Moreover, interactions can give rise to an asymmetry between
absorption and emission peaks. In the contact driven case, the theory predicts
a zero-bias current proportional to the asymmetry of the double barrier. This
is in contrast to the discussion of Tien and Gordon which, in violation of
basic symmetry principles, predicts a zero-bias current also for a symmetric
double barrier.Comment: 15 pages, 6 figures, REVTE
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
Summary Background Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT). Fexinidazole, the latest treatment that has been recommended by WHO, also requires systematic admission to hospital, which is problematic in areas with few health-care resources. We aim to assess the safety and efficacy of acoziborole in adult and adolescent patients with gambiense HAT. Methods This multicentre, prospective, open-label, single-arm, phase 2/3 study recruited patients aged 15 years or older with confirmed gambiense HAT infection from ten hospitals in the Democratic Republic of the Congo and Guinea. Inclusion criteria included a Karnofsky score less than 50, ability to swallow tablets, a permanent address or traceability, ability to comply with follow-up visits and study requirements, and agreement to hospital admission during treatment. Oral acoziborole was administered as a single 960 mg dose (3 × 320 mg tablets) to fasted patients. Patients were observed in hospital until day 15 after treatment administration then for 18 months as outpatients with visits at 3, 6, 12, and 18 months. The primary efficacy endpoint was the success rate of acoziborole treatment at 18 months in patients with late-stage gambiense HAT (modified intention-to-treat [mITT] population), based on modified WHO criteria. A complementary post-hoc analysis comparing the 18-month success rates for acoziborole and NECT (using historical data) was performed. This study is registered at ClinicalTrials.gov, NCT03087955. Findings Between Oct 11, 2016, and March 25, 2019, 260 patients were screened, of whom 52 were ineligible and 208 were enrolled (167 with late-stage and 41 with early-stage or intermediate-stage gambiense HAT; primary efficacy analysis set). All 41 (100%) patients with early-stage or intermediate-stage and 160 (96%) of 167 with late-stage disease completed the last 18-month follow-up visit. The mean age of participants was 34·0 years (SD 12·4), including 117 (56%) men and 91 (44%) women. Treatment success rate at 18 months was 95·2% (95% CI 91·2-97·7) reached in 159 of 167 patients with late-stage gambiense HAT (mITT population) and 98·1% (95·1-99·5) reached in 159 of 162 patients (evaluable population). Overall, 155 (75%) of 208 patients had 600 treatment-emergent adverse events. A total of 38 drug-related treatment-emergent adverse events occurred in 29 (14%) patients; all were mild or moderate and most common were pyrexia and asthenia. Four deaths occurred during the study; none were considered treatment related. The post-hoc analysis showed similar results to the estimated historical success rate for NECT of 94%. Interpretation Given the high efficacy and favourable safety profile, acoziborole holds promise in the efforts to reach the WHO goal of interrupting HAT transmission by 2030. Funding Bill & Melinda Gates Foundation, UK Aid, Federal Ministry of Education and Research, Swiss Agency for Development and Cooperation, Médecins Sans Frontières, Dutch Ministry of Foreign Affairs, Norwegian Agency for Development Cooperation, Norwegian Ministry of Foreign Affairs, the Stavros Niarchos Foundation, Spanish Agency for International Development Cooperation, and the Banco Bilbao Vizcaya Argentaria Foundation. Translation For the French translation of the abstract see Supplementary Materials section
Human embryonic stem cells and derived contractile embryoid bodies are susceptible to Coxsakievirus B infection and respond to interferon Iβ treatment
We studied the susceptibility of human embryonic stem cells and derived contractile embryoid bodies from WAO9, HUES-5 and HUES-16 cell lines to Coxsackievirus B infection. After validating stem cell-like properties and cardiac phenotype, Coxsackievirus B receptors CAR and DAF, as well as type I interferon receptors were detected in all cell lines and differentiation stages studied. Real-time PCR analysis showed that CAR mRNA levels were 3.4-fold higher in undifferentiated cells, while DAF transcript levels were 2.78-fold more abundant in differentiated cultures (P5-106 plaque forming units (PFU)/ml, the highest titers were detected in undifferentiated cells. Cell viability detected by a colorimetric assay, showed inverse correlation with infectivity titers of cell culture supernatants. Treatment with 100 U of interferon Iβ significantly reduced viral replication and associated cell death during a 24-48 h observation period, as detected by reduced infectivity titers in the supernatants and increased cell viability by a colorimetric assay, respectively. We propose human embryonic stem cell and derived contractile embryoid bodies as a valid model to study cardiac Coxsackievirus B infection.Instituto de Biotecnologia y Biologia MolecularFacultad de Ciencias Exacta
- …